Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of two fixed-dose combination tablets of empagliflozin 25 mg + linagliptin 5 mg in healthy Thai subjects (fasting)
TCTR20230405007Phase 1Completed
- Sponsor
- Camber Pharmaceuticals
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Camber Pharmaceuticals. Started Aug 2023; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20230405007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230405007.